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Abstract: Cancer is known to induce or alter the O-glycosylation of selective proteins that 
may eventually be excreted in the patients’ urine. The present study was performed to 
identify O-glycosylated proteins that are aberrantly excreted in the urine of patients with 
early stage ovarian cancer (OCa). These urinary glycoproteins are potential biomarkers for 
early detection of OCa. In this study, urinary proteins of patients with early stage OCa and 
age-matched OCa negative women were subjected to two-dimensional gel electrophoresis 
and detection using a lectin that binds to the O-glycosylated proteins. Our analysis 
demonstrated significant enhanced expression of clusterin and leucine-rich  
alpha-2-glycoprotein, but lower levels of kininogen in the urine of the OCa patients 
compared to the controls. The different altered levels of these urinary glycoproteins were 
further confirmed using competitive ELISA. Our data are suggestive of the potential use of 
the aberrantly excreted urinary O-glycosylated proteins as biomarkers for the early 
detection of OCa, although this requires further validation in a large clinically 
representative population. 
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1. Introduction 
Ovarian cancer (OCa) is the fifth most prevalent cause of cancer death in women [1]. The five-year 
survival rate of patients diagnosed at an advanced stage is approximately 30%, and this increases to 
more than 90% if the patients were diagnosed at stage I [2]. Currently, diagnosis of OCa is mainly 
reliant on imaging methods and assessment of tumor markers. However, CA125, the main tumor marker 
used in the diagnosis of OCa, is also elevated in numerous other cancers and benign conditions [3]. In 
addition, the tumor marker is not adequately sensitive for early detection, as many women with early 
stage OCa have normal CA125 levels [4]. In view of these limitations, there is a need to identify new 
biomarkers that are more specific and sensitive, which can improve diagnosis of early stage OCa and, 
hence, the survival rates of the patients.  
The collection of human urine is more convenient and non-invasive compared to serum, plasma or 
tissue specimens. This makes it one of the preferred sample choices for diagnostic purposes. Attempts 
to identify protein biomarkers in the urine are gaining popularity, particularly with the advancement of 
proteomics technology. This includes profiling of the urine protein samples by two-dimensional  
gel electrophoresis (2-DE) and identification of the proteins that are aberrantly expressed using  
MALDI-ToF or other mass spectrometry techniques and searches of databases. Research using these 
approaches is not restrictive to the screening for biomarkers, but also improves understanding of the 
disease and, perhaps, the management and treatment of cancer.  
O-glycosylation is an enzymatic reaction in which a glycan moiety is attached to the serine or 
threonine residues of a protein. The attached O-glycans greatly influence the stability and tertiary 
structures of the glycoproteins and, hence, their functions in the biological system. Many serum  
O-glycosylated proteins have been previously implicated in cancer [5–7], either in the form of their 
altered O-glycan structures or their levels. These findings not only provide meaningful information 
about cancer development, but the glycoproteins that are modified may also be exploited for their 
potential use as cancer biomarkers.  
The aim of the present study was to screen for potential O-glycosylated protein biomarkers in the 
urine of patients with OCa using the lectin-based proteomics approach. Urine samples of untreated and 
newly diagnosed patients with early stage OCa, as well as OCa negative women subjects, were  
initially subjected to 2-DE separation. This was followed by Western blotting and detection using an  
enzyme-conjugated champedak galactose binding (CGB) lectin. The CGB lectin, which binds 
specifically to the O-glycan structures [8,9], was used to probe for the O-glycans of glycoproteins. The  
O-glycosylated proteins that were found to be aberrantly excreted in the urine of the OCa patients were 
then identified by mass spectrometry and database search.  
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2. Results  
2.1. Image Analysis of O-glycosylated Protein Profiles  
Profiles of O-glycosylated proteins of the OCa patients and controls were generated using  
enzyme-conjugated CGB lectin to bind to the urinary proteins that had been separated by 2-DE and 
transferred onto nitrocellulose membrane. Figure 1 demonstrates representatives of the O-glycosylated 
protein profiles of control subjects (Panel A) and OCa patients (Panel B). The 2-DE profiles of the 
patients and controls appeared comparable, except for three clusters of urinary O-glycosylated 
proteins. Two of the glycoprotein clusters appeared to be exclusively present in the profiles of the OCa 
patients, while the intensity of one protein cluster was consistently reduced compared to that of the 
control subjects. 
Figure 1. Two-dimensional gel electrophoresis (2-DE) O-glycosylated protein profiles of 
controls and ovarian cancer (OCa) patients. Panels A and B demonstrate representative  
2-DE urinary O-glycosylated protein profiles of controls and OCa patients, respectively. 
Protein clusters that were labeled (clusterin (CLU), leucine-rich alpha-2-glycoprotein 
(LRG) and kininogen (KNG)) are those found to be aberrantly excreted in the urine of the 
patients. The acidic side of the gel is to the left, and relative molecular mass is from the top. 
 
Subjecting the two upregulated O-glycosylated proteins to mass spectrometric (MS) analysis  
and database search identified the glycoproteins as those of clusterin (CLU) and leucine-rich  
alpha-2-glycoprotein (LRG) (Table 1). Data for the identification of the kininogen (KNG) spot cluster 
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had been previously reported [7]. Analysis of the volumes of the proteins showed that the levels of 
LRG and CLU in the OCa patients were both 17-fold higher than the controls, while the level of the 
patients’ KNG was six-fold lower than the controls (Table 2). 
















P02750 38/6.45 149 10 
§ CLU Clusterin P10909 52/5.89 25 11 
Protein entry names are from the UniProtKB database; # Accession numbers are from the Mascot search engine;  
§ On-membrane digestion. 
Table 2. Relative expression of aberrantly excreted urinary O-glycosylated proteins.  
O-Glycosylated protein 
Mean %vol ± SEM 
p Fold changes 
Control OCa 
LRG 0.120 ± 0.077 2.06 ± 0.298 0.000004 +17.17 
CLU 0.105 ± 0.080 1.821 ± 0.356 0.0001 +17.34 
KNG 10.135 ± 2.163 1.638 ± 0.505 0.004 –6.19 
2.2. Competitive ELISA 
Competitive ELISA was performed using monoclonal antisera against LRG, CLU and KNG to 
validate the altered levels of the urinary proteins that were detected in the patients with OCa (n = 9) 
compared to the control subjects (n = 11). Figure 2 demonstrates the mean percentage of inhibition of 
LRG, CLU and KNG that were tested in respective groups of samples. The expression of LRG and 
CLU was significantly enhanced, whilst KNG was found to be decreased in almost all of the urine 
samples of the OCa patients compared to the controls.  
Figure 2. Mean percentage of inhibition of urinary LRG, CLU and KNG in controls (Con) 
and patients with OCa. Analysis was performed by competitive ELISA. The concentrations 
of LRG and CLU in the urine samples of OCa patients were significantly higher than those 
of the controls, while KNG was significantly lower in the OCa patients. The concentrations 
of proteins present in the samples were proportional to the percentage inhibition of 
substrate hydrolysis. Asterisk denotes the statistical significance with p < 0.05. 
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3. Discussion 
The finding of altered levels of glycoproteins, which are potential biomarkers, may not only 
improve diagnosis and the survival rates of patients suffering from OCa, but also provide more insights 
into the molecular mechanisms of the disease. In the present study, the significant increased levels of 
LRG and CLU and decreased levels of KNG were detected in the urine samples of OCa patients 
compared to those of the controls when image analysis was performed on the CGB lectin-detected  
O-glycosylated proteins that were separated by 2-DE and transferred onto nitrocellulose membranes. 
The significant altered expression of the three urinary O-glycosylated proteins in the OCa patients was 
further confirmed using competitive ELISA. 
The altered levels of urinary LRG and CLU that were detected in the present study have been 
previously observed in the sera of patients with OCa [10]. Hence, it is reasonable to postulate that the 
increase of both the glycoproteins in the urine of the OCa patients’ may be reflective of changes that 
had occurred in their serum.  
LRG is a secreted protein with regions containing leucine-rich repeats. It is mainly produced by the 
liver cells in response to cancer, but its synthesis by OCa cells has also been documented [11]. The 
actual functions of LRG are still unknown, although the glycoprotein has been associated with cell 
adhesion, granulocytic differentiation, cell migration, cell survival, protein interaction and signal 
transduction [12]. The O-glycosylated protein was also proposed to be involved in the acute-phase 
response, since its level was reported to be elevated in patients with microbial infection, as well as 
those afflicted with several different cancers, including OCa [11].  
Increased levels of CLU have been previously observed in the sera of patients with OCa, as well as 
those with other types of cancers [10,13,14]. CLU, also known as apolipoprotein J, has been implicated in 
diverse physiological functions. Its expression was previously reported to be associated with regulation 
of the cell cycle, cell damage recovery, cell survival, senescence, tumorigenesis and apoptosis [15]. 
Our present data demonstrated increased levels of CLU in the urine of the OCa patients. 
KNG is a protein containing two isoforms produced by alternative mRNA splicing [16]. Based on 
the molecular weight of the 2-DE separated glycoprotein that was observed on the membrane, the 
KNG that was detected in the present study was most likely its light chain component that is also 
known to be O-glycosylated. The decreased in the levels of KNG in the urine of OCa patients has been 
previously reported, and this was suggested to act as compensation to the mechanisms of angiogenesis 
and cell proliferation, because KNG was shown to inhibit angiogenesis, as well as the proliferation of 
endothelial cells [17]. In addition to the data of these studies, there have also been a number of similar 
reports on the decreased levels of KNG in patients with cervical cancer [5], breast cancer [14] and 
gastrointestinal cancer [18]. 
4. Experimental Section  
4.1. Urine Samples and Processing 
Urine samples from newly diagnosed patients with stages I and II OCa (n = 9) were collected at the 
Gynecological Clinic, University of Malaya Medical Centre, Kuala Lumpur, prior to any treatment or 
surgery. Table 3 demonstrates the clinical data of the OCa patients involved in the study. The 
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processing of the samples was performed as previously described [9]. Patients with any other diseases 
aside from OCa were excluded from the study.  
Table 3. Clinical data of OCa patients involved in the study. 
OCa patient Stage Age Late menopause Previous pregnancy Early puberty Blood creatinine 
1 I 48 No Yes No Normal 
2 I 56 No Yes No Normal 
3 I 62 No Yes No Normal 
4 I 70 No Yes No Normal 
5 I 81 No Yes No Normal 
6 II 46 No Yes No Normal 
7 II  54 No Yes No Normal 
8 II 68 No Yes No Normal 
9 II 47 No Yes No Normal 
Control urine samples (n = 11, ages of 30–75) were obtained randomly from OCa negative women. 
All samples were obtained with the subjects’ consent and approval granted by the Ethical Committee 
of UMMC in accordance to the ICH GCP guideline and the declaration of Helsinki. 
4.2. Isolation of CGB Lectin 
CGB lectin was purified as previously described [7,8]. Briefly, crude extracts of the seeds of 
champedak were prepared by stirring of homogenized seeds in PBS, pH 7.4, overnight, and subjecting 
the supernatant to 60% ammonium sulfate precipitation. The crude extract was then subjected to 
immobilized galactose affinity chromatography, and elution of the CGB lectin was performed using  
0.8 M galactose. Purity of the eluted lectin was confirmed by SDS-PAGE. The purified lectin was then 
conjugated to horse radish peroxidase before it was used in Western blot analysis. 
4.3. Two-Dimensional Electrophoresis 
Urinary proteins of patients and controls were resolved using 2-DE, which was performed as 
previously described [19]. Briefly, 300 µg of freeze dried urine samples were subjected to isoelectric 
focusing in 11 cm rehydrated precast Immobiline Drystrips pH 3–10 using the IPGphor 3 equipment 
(GE Healthcare Biosciences, Uppsala, Sweden). This was followed by electrophoretic separation of the 
focused protein samples in the second dimension in 12.5% polyacrylamide gels in the presence of SDS.  
4.4. Western Blotting and Lectin Detection 
Glycoproteins were transferred from 2-DE gels onto nitrocellulose membranes (0.45 µm) using the 
NovaBlot Kit of Multiphor II Electrophoresis system (GE Healthcare Bioscience, Uppsala, Sweden) at 
0.8 mA/cm2 for 1 h. The membrane was blocked with 3% w/v gelatin in Tris-buffered saline Tween-20 
(TBST), pH 7.5, for 1 h at room temperature and washed three times with the same buffer. Detection 
of transferred O-glycosylated urinary proteins was performed using horseradish peroxidase-conjugated 
CGB lectin. Blots were developed using a metal enhanced diaminobenzidine (DAB) substrate kit for 
horseradish peroxidase (Pierce, Rockford, IC, USA). 
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4.5. Image Analysis 
The lectin blots were scanned using the ImageScanner III (GE Healthcare Bioscience, Uppsala, 
Sweden). Image analysis was restricted to protein spot clusters that appeared consistently within each 
group of urine samples. The levels of proteins in each sample were calculated as a percentage of 
volume contribution (%vol). This refers to the volume percentage of a protein taken against the total 
spot volume of all proteins. The %vol was used in order to eliminate possible variations in the total 
amounts of proteins analyzed. The Student’s t-test was used to analyze the significance difference of 
the %vol of a spot/protein cluster between the controls and OCa patients. A p-value of less than 0.05 
was initially considered significant. Correction of false positive discoveries was then carried out based 
on the method of Benjamini and Hochberg [20]. Consequently, a p-value of less than 0.022 was 
subsequently considered to be significant. 
4.6. MALDI-ToF Mass Spectrometry 
Identification of proteins was performed by mass spectrometry and database search. The 2-DE gels 
were silver stained according to the method of Shevchenko et al. [21]. In-gel digestion of protein plugs 
from 2-DE gels was carried out according to a previously described method [22]. On the other hand, 
on-membrane digestion was performed according to the method described by Mu et al. [7]. The 
MALDI mass spectrometry was performed using the Applied Biosystem 4800 Proteomics Analyzer. 
The MS/MS data were then submitted to the MASCOT search engine for protein identification. 
Proteins were considered positively identified, as described by Delahunty and Yates [23]. 
4.7. Competitive ELISA 
The altered levels of LRG, CLU and KNG were validated using competitive ELISA, as described 
by Doustjalali et al. [13], with slight modifications. Wells of microtiter plates (Nunc, Denmark) were 
coated with 10 µg urinary protein in 0.05 M sodium bicarbonate buffer pH 9.6 overnight at 4 °C. The 
wells were rinsed extensively with 100 μL of PBST three times. This was followed by blocking with 
100 μL of 0.5% gelatin in the same buffer for 30 min at room temperature. After blocking, the plates 
were washed, and the wells were filled with mouse anti-human LRG, CLU and KNG in the presence 
of controls’ (n = 11) and patients’ (n = 9) urine samples at a dilution of 1:1000 for 1 h at room 
temperature. Positive controls and blanks were prepared in the absence of urine samples and by 
addition of washing buffer, respectively. After incubation, each well was washed extensively with 
washing buffer. This was followed by the addition of 200 μL of horseradish peroxidase-conjugated 
secondary anti-mouse IgG at 1:5000 dilution. The plates were incubated for another 1 h at room 
temperature before they were washed extensively with washing buffer. One hundred μL of  
3,3',5,5'-tetramethylbenzidine substrate (Sigma Aldrich, St. Louis, MO, USA) was added to each well, 
and the plates were incubated for 15 min at room temperature in the dark. The reaction was terminated 
with the addition of 100 μL 2 M sulfuric acid. Absorbance values were read at 450 nm using an ELISA 
plate reader. The amounts of the respective proteins in the urine samples were determined based on the 
percentage of inhibition of substrate hydrolysis [24]. 
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5. Conclusions 
The present study identified the different altered expression of LRG, CLU and KNG in the urine of 
a group of patients with early stage OCa, which may be used as complementary biomarkers for early 
detection of the cancer. Our findings also emphasize the need for further epidemiological validation 
studies to assess the sensitivity and specificity of the potential urinary biomarkers for the early stage 
diagnosis of OCa.  
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